Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β
about
Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Subcutaneous liraglutide ameli ...... nd glycogen synthase kinase-3β
@en
Subcutaneous liraglutide ameli ...... d glycogen synthase kinase-3β.
@nl
type
label
Subcutaneous liraglutide ameli ...... nd glycogen synthase kinase-3β
@en
Subcutaneous liraglutide ameli ...... d glycogen synthase kinase-3β.
@nl
prefLabel
Subcutaneous liraglutide ameli ...... nd glycogen synthase kinase-3β
@en
Subcutaneous liraglutide ameli ...... d glycogen synthase kinase-3β.
@nl
P2093
P2860
P1476
Subcutaneous liraglutide ameli ...... nd glycogen synthase kinase-3β
@en
P2093
Linfang Ke
Xiaohong Liu
Xiaowei Lin
Xiaoying Liu
Yanping Wang
Zhongjie Zheng
P2860
P304
P407
P577
2017-02-15T00:00:00Z